Payment overview · 2025
General Payments
$883.22
55 reported records · 19 companies
Healthcare provider profile · identity verified
Kenneth M Faile, MD
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSONVILLE, SC · NPI 1750354858
Verified facts
What the public records show
CMS Open Payments records show Kenneth M Faile, MD received $883.22 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Otezla, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.64 | 21.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.88 | 19.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.75 | 10.1% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $56.08 | 6.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.88 | 5.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.92 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.99 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.27 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.84 | 3.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.67 | 3.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $23.97 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.41 | 2.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.37 | 2.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.33 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.46 | 2.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.39 | 1.7% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.87 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.33 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.17 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $839.97 | 54 |
| Education | $43.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.02 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.87 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $56.08 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.28 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.92 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $43.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.82 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9.86 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $0.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 190 |
| Tramadol Hcl | Tramadol Hcl | 611 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 170 |
| Lisinopril | Lisinopril | 464 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 458 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 99 |
| Omeprazole | Omeprazole | 368 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 355 | 103 |
| Alprazolam | Alprazolam | 327 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 319 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 284 | 83 |
| Furosemide | Furosemide | 283 | 74 |
| Gabapentin | Gabapentin | 276 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 274 | 87 |
| Metformin Hcl | Metformin Hcl | 268 | 71 |
| Ibuprofen | Ibuprofen | 259 | 96 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 249 | 38 |
| Metformin Hcl Er | Metformin Hcl | 230 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 227 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 86 |
| Citalopram Hbr | Citalopram Hydrobromide | 222 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 62 |
| Lorazepam | Lorazepam | 186 | 33 |
| Carvedilol | Carvedilol | 175 | 51 |
| Glipizide Er | Glipizide | 173 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 49 |
| Losartan Potassium | Losartan Potassium | 168 | 51 |
| Famotidine | Famotidine | 167 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 154 | 78 |
| Potassium Chloride | Potassium Chloride | 149 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 41 |
| Clonazepam | Clonazepam | 141 | 19 |
| Simvastatin | Simvastatin | 137 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 39 |
| Eliquis | Apixaban | 135 | 35 |
| Diazepam | Diazepam | 134 | 25 |
| Meclizine Hcl | Meclizine Hcl | 130 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 121 | 35 |
| Ozempic | Semaglutide | 116 | 20 |
| Ezetimibe | Ezetimibe | 114 | 32 |
| Meloxicam | Meloxicam | 111 | 30 |
| Trazodone Hcl | Trazodone Hcl | 110 | 35 |
| Prednisone | Prednisone | 108 | 65 |
| Allopurinol | Allopurinol | 106 | 28 |
| Cefdinir | Cefdinir | 106 | 83 |
| Montelukast Sodium | Montelukast Sodium | 106 | 31 |
| Clonidine Hcl | Clonidine Hcl | 105 | 23 |
| Nifedipine Er | Nifedipine | 99 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 21 |
| Fluconazole | Fluconazole | 92 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 29 |
| Linzess | Linaclotide | 87 | 24 |
| Sertraline Hcl | Sertraline Hcl | 87 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 86 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 56 |
| Donepezil Hcl | Donepezil Hcl | 76 | 23 |
| Benazepril Hcl | Benazepril Hcl | 75 | 19 |
| Jardiance | Empagliflozin | 75 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 32 |
| Cephalexin | Cephalexin | 71 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 20 |
| Colchicine | Colchicine | 67 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 21 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Trulicity | Dulaglutide | 65 | 11 |
| Pregabalin | Pregabalin | 62 | 16 |
| Mirtazapine | Mirtazapine | 61 | suppressed |
| Levofloxacin | Levofloxacin | 60 | 46 |
| Bupropion Xl | Bupropion Hcl | 58 | 18 |
| Januvia | Sitagliptin Phosphate | 58 | 14 |
| Spironolactone | Spironolactone | 58 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | 13 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 19 |
| Azithromycin | Azithromycin | 52 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Finasteride | Finasteride | 49 | 17 |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | 23 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 11 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Topiramate | Topiramate | 37 | suppressed |
| Sucralfate | Sucralfate | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Lactulose | Lactulose | 31 | 16 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Metronidazole | Metronidazole | 29 | 18 |
| Atenolol | Atenolol | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Dofetilide | Dofetilide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 11 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | 15 |
| Otezla | Apremilast | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $883.22 · 55 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, ELIQUIS, ENHERTU, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Heplisav-B, IBSRELA, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XYOSTED, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error